Success Metrics

Clinical Success Rate
66.7%

Based on 2 completed trials

Completion Rate
67%(2/3)
Active Trials
0(0%)
Results Posted
0%(0 trials)
Terminated
1(33%)

Phase Distribution

Ph phase_3
1
33%
Ph phase_2
1
33%
Ph phase_1
1
33%

Phase Distribution

1

Early Stage

1

Mid Stage

1

Late Stage

Phase Distribution3 total trials
Phase 1Safety & dosage
1(33.3%)
Phase 2Efficacy & side effects
1(33.3%)
Phase 3Large-scale testing
1(33.3%)

Highest Phase Reached

Phase 3

Trial Status & Enrollment

Completion Rate

66.7%

2 of 3 finished

Non-Completion Rate

33.3%

1 ended early

Currently Active

0

trials recruiting

Total Trials

3

all time

Status Distribution
Completed(2)
Terminated(1)

Detailed Status

Completed2
Terminated1

Development Timeline

Analytics

Development Status

Total Trials
3
Active
0
Success Rate
66.7%
Most Advanced
Phase 3

Trials by Phase

Phase 11 (33.3%)
Phase 21 (33.3%)
Phase 31 (33.3%)

Trials by Status

terminated133%
completed267%

Recent Activity

0 active trials
Showing 3 of 3
completedphase_1

Tas-102 and Radioembolization With 90Y Resin Microspheres for Chemo-refractory Colorectal Liver Metastases

NCT02602327
completedphase_3

SorAfenib Versus RADIOEMBOLIZATION in Advanced Hepatocellular Carcinoma

NCT01482442
terminatedphase_2

Brachytherapy Radiation Directly to the Liver in Breast Cancer Patients With Metastatic to Liver

NCT00891800

Clinical Trials (3)

Showing 3 of 3 trials
NCT02602327Phase 1

Tas-102 and Radioembolization With 90Y Resin Microspheres for Chemo-refractory Colorectal Liver Metastases

Completed
NCT01482442Phase 3

SorAfenib Versus RADIOEMBOLIZATION in Advanced Hepatocellular Carcinoma

Completed
NCT00891800Phase 2

Brachytherapy Radiation Directly to the Liver in Breast Cancer Patients With Metastatic to Liver

Terminated

All 3 trials loaded

Drug Details

Intervention Type
DEVICE
Total Trials
3